Upstream Bio (Nasdaq: UPB), a clinical-stage biotech company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Rand Sutherland will engage in a fireside chat on June 11, 2025, at 9:20 a.m. ET. The presentation will be accessible via live webcast in the Events section of the company's Investors page, with a replay available afterward.
Upstream Bio (Nasdaq: UPB), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di trattamenti per malattie infiammatorie e gravi disturbi respiratori, ha annunciato la sua partecipazione alla 46陋 Conferenza Globale Annuale sulla Sanit脿 di Goldman Sachs. Il CEO Rand Sutherland parteciper脿 a una conversazione informale il 11 giugno 2025 alle 9:20 ET. La presentazione sar脿 disponibile in diretta streaming nella sezione Eventi della pagina Investitori dell'azienda, con la possibilit脿 di rivederla successivamente.
Upstream Bio (Nasdaq: UPB), una empresa biotecnol贸gica en etapa cl铆nica enfocada en desarrollar tratamientos para enfermedades inflamatorias y trastornos respiratorios graves, ha anunciado su participaci贸n en la 46陋 Conferencia Global Anual de Salud de Goldman Sachs. El CEO Rand Sutherland participar谩 en una charla informal el 11 de junio de 2025 a las 9:20 a.m. ET. La presentaci贸n estar谩 disponible en transmisi贸n en vivo en la secci贸n de Eventos de la p谩gina de Inversores de la compa帽铆a, con una repetici贸n disponible posteriormente.
Upstream Bio (Nasdaq : UPB), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans le d茅veloppement de traitements pour les maladies inflammatoires et les troubles respiratoires s茅v猫res, a annonc茅 sa participation 脿 la 46e conf茅rence annuelle mondiale sur la sant茅 de Goldman Sachs. Le PDG Rand Sutherland participera 脿 une discussion informelle le 11 juin 2025 脿 9h20 (heure de l'Est). La pr茅sentation sera accessible en webcast en direct dans la section 脡v茅nements de la page Investisseurs de l'entreprise, avec une rediffusion disponible par la suite.
Upstream Bio (Nasdaq: UPB), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien f眉r entz眉ndliche Erkrankungen und schwere Atemwegserkrankungen spezialisiert hat, hat seine Teilnahme an der 46. j盲hrlichen Global Healthcare Conference von Goldman Sachs angek眉ndigt. CEO Rand Sutherland wird am 11. Juni 2025 um 9:20 Uhr ET an einem informellen Gespr盲ch teilnehmen. Die Pr盲sentation wird als Live-Webcast im Bereich Events auf der Investorenseite des Unternehmens verf眉gbar sein, mit anschlie脽ender Wiederholung.
Positive
None.
Negative
None.
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET.
A live webcast of the fireside chat will be available under the 鈥溾�� tab on the 鈥淚nvestors鈥� page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation.
About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio鈥檚 team is committed to maximizing verekitug鈥檚 unique attributes to address the substantial unmet needs for patients underserved by today鈥檚 standard of care. To learn more, please visit .
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
[email protected]
FAQ
When is Upstream Bio (UPB) presenting at the Goldman Sachs Healthcare Conference 2025?
Upstream Bio will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET.
Who will represent Upstream Bio (UPB) at the Goldman Sachs Healthcare Conference?
Dr. Rand Sutherland, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the conference.
How can I watch Upstream Bio's (UPB) presentation at the Goldman Sachs Conference?
The presentation can be viewed via live webcast under the Events tab on the Investors page of Upstream Bio's website, with a replay available after the event.
What is Upstream Bio's (UPB) main focus as a company?
Upstream Bio is a clinical-stage company that develops treatments for inflammatory diseases, with a particular focus on severe respiratory disorders.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
